XML 53 R37.htm IDEA: XBRL DOCUMENT

ACQUISITIONS AND LICENSING AGREEMENTS (Tables)

12 Months Ended

Dec. 31, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

Schedule of aggregate acquisition consideration

The total aggregate acquisition consideration of approximately $188 million is calculated as follows:


(in millions)
Cash consideration paid	$	99
Estimated fair value of contingent consideration	89
Aggregate purchase consideration	$	188

The estimated aggregate acquisition consideration of approximately $1,753 million is calculated as follows:


(in millions)
Cash consideration paid to Novartis at closing, per the Acquisition Agreement	$	1,750
Estimated fair value of contingent consideration	3
Aggregate purchase consideration	$	1,753

Schedule of fair values of assets acquired and liabilities assumed

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of Elios Vision, as of the acquisition date:


(in millions)
Intangible assets, net	$	177
Trade receivables, net	2
Inventories, net	4
Property, plant and equipment, net	7
Other non-current assets	1
Accrued and other current liabilities	(7)
Other non-current liabilities	(23)
Total identifiable net assets	161
Goodwill	27
Total fair value of consideration transferred	$	188

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the XIIDRA Acquisition as of the acquisition date, inclusive of measurement period adjustments:


(in millions)
Intangible assets, net	$	1,600
Prepaid expenses and other current assets	162
Accrued and other current liabilities	(1)
Other non-current liabilities	(31)
Total identifiable net assets	1,730
Goodwill	23
Total fair value of consideration transferred	$	1,753

Schedule of intangible assets acquired

The intangible assets acquired related to the acquisition of Elios Vision, as well as their fair values and estimated useful life consist of the following:


(in millions)	Fair Value		Estimated Useful Life (In Years)
Acquired in-process research and development intangible asset	$	95	N/A
Product brands	63		13
Corporate brands	17		10
Other	2		9
Total Intangible assets, net	$	177

The intangible assets acquired related to the acquisition of Trukera Medical, as well as their fair values and estimated useful life consist of the following:


(in millions)	Fair Value		Estimated Useful Life (In Years)
Product Brand	$	14	10
Customer Relationships	2		7
Total Intangible assets, net	$	16

The intangible assets acquired, as well as their fair values and estimated useful life consist of the following:


(in millions)	Fair Value		Estimated Useful Life (In Years)
Product brand	$	1,595	8.75
Acquired in-process research and development intangible asset	5		N/A
Total Intangible assets, net	$	1,600

The intangible assets acquired and estimated useful lives consist of the following:


(in millions)			Estimated Useful Life (In Years)
Corporate brands	$	73	12
Product brands	12		10
Technology and other	6		9
Total Intangible assets, net	$	91

Schedule of pro forma information

The following table presents the unaudited pro forma combined results of the Company and the acquired assets for the years ended December 31, 2023 and 2022 as if the XIIDRA Acquisition, and the related financing, had occurred on January 1, 2022:


(in millions)	2023		2022
Revenues	$	9,006	$	8,611
Net loss	$	(822)	$	(507)
Net loss attributable to Bausch Health Companies Inc.	$	(762)	$	(498)